22nd Century Group, Inc (AMEX:XXII) is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.04 per share from revenue of $ 5.50 million.
Looking ahead, the full year loss are expected at $ 0.14 per share on the revenues of $ 24.99 million.
Previous Quarter Performance
22nd Century Group, Inc outlined loss for the second quarter of $ 0.04 per share, from the revenue of $ 6.40 million. The consensus estimates are loss of $ 0.04 per share from $ 5.00 million in revenue. The top line results outshined analysts by $ 1.40 million or 28.00 percent.
Stock Performance
Shares of 22nd Century Group, Inc traded up $ 0.04 or 5.55 percent on Wednesday, reaching $ 0.74 with volume of 738.90 thousand shares. 22nd Century Group, Inc has traded high as $ 0.76 and has cracked $ 0.71 on the downward trend
The closing price of $ 0.74, representing a 27.27 % increase from the 52 week low of $ 0.55 and a 60.89 % decrease over the 52 week high of $ 1.79.
The company has a market capital of $ 102.46 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
22nd Century Group, Inc will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.xxiicentury.com
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies. The companys products under development include BRAND A, a very low nicotine content cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette.
